at Benzinga.com (Jan 12, 2015)
Jefferies lifts it price target on Jazz Pharmaceuticals (JAZZ) to $64 from $56 on its belief that the firm can beat its own guidance with its reconfigured sales structure. Analysts also raise their EPS estimates for Jazz for FY12 and FY13 by $0.04 and $0.73, respectively.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Jan 8, 2015)
at Investor's Business Daily (Dec 15, 2014)
at Zacks.com (Dec 15, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs